Phase II Evaluation of Oral ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma.
Patients receive open-label ALRT1057 for 16 weeks, as tolerated. In the absence of
unacceptable toxicity, patients may continue treatment indefinitely provided they continue
to benefit from therapy and the study remains open and active.
Thirteen patients are treated initially. If at least one response is observed in these
patients, up to 14 additional patients will be evaluated.
Endpoint Classification: Safety Study, Primary Purpose: Treatment
United States: Food and Drug Administration